Clinical trial

Iressa as Second Line Therapy in Advanced NSCLC-Asia

NCT00478049

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-09-01

PhasePHASE3

Study timeline

Study start (unknown)2005-09-01Date precision: month

Registry last updated2012-06-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLCunresolved

Interventions

GefitinibDRUG · verified · RxNorm: gefitinib

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

SeoulSouth Korea1 IncheonSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00478049 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.